Anorexia Nervosa, Bulimia Nervosa
Conditions
Brief summary
Background. Treatments of eating disorders result too often in partial psychological and physical remission, chronic course, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this problem, we conducted a three branches study to identify the biochemical background of cognitive-behavioral psychotherapy (CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT+olanzapine in anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion, plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet \[3 Hydrogen\]-Paroxetine-binding Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and physical alterations. Methods. Branch 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and \[3 Hydrogen\]-Par-binding in 14 AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Branch 2 investigated the effects of 4 months of IBPP on plasma HVA in 15 AN and 17 BN outpatients. Branch 3 investigated the effect of 3 months of CBT+olanzapine (5 mg/day) in 30 AN outpatients. The data are analyzed using one-way ANOVA for repeated measures for the changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated measures for the differences in the psychobiological data in the 3 groups, Spearman's test for the correlations between basal and final changes in the psychological and biological scores.
Interventions
It is a worldwide known form of psychotherapy for eating disorders
It is a worldwide known form of psychotherapy for eating disorders
It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
all patients were followed-up monthly with nutritionist and dietitian visits
all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
Sponsors
Study design
Eligibility
Inclusion criteria
* eating disorders full diagnosis according to Diagnostic and Statistical Manual (DSM-IV) * age between 15 and 35 * female gender
Exclusion criteria
* associated major psychiatric problems * mental retardation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| change in brain secretion of Dopamine at 6 months | 6 months | plasma homovanillic acid (HVA) measured before and after the therapeutic intervention in each branch. |
| change in brain secretion of Noradrenaline at 6 months | 6 months | plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) measured before and after the therapeutic intervention in each branch |
| change in brain secretion of serotonin at 6 months | 6 months | the platelet paroxetine binding (\[3 Hydrogen\]-Par-binding): Bmax (maximum binding capacity) and Kd (dissociation constant) measured before and after the therapeutic intervention in each branch. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Impulsiveness improvement after 6 months | 6 months | Barratt Impulsiveness Scale |
| Eating Psychopathology improvement after treatments at 6 months | 6 months | Eating Disorders Examination-12 (EDE 12) |
| Personality improvement after 6 months | 6 months | Temperament and Character Inventory (TCI) |
| Self-rated Biochemical improvement after 6 months | 6 months | Rosenberg Self-Biochemical Scale |
| Depressive Psychopathology improvement after 6 months | 6 months | Beck Depression Inventory (BDI) |
| Anxiety improvement after 6 months | 6 months | State-Trait Anxiety Index (STAI) Form-Y-1 |
Countries
Italy